Company intelligence / Profile preview

Sinopharm Nuoh

Beijing, Beijing, China

Ownership: Private
Development stage: Other

Overview

Sinopharm Nuoh (Beijing) Medical Technology is a clinical-stage biopharmaceutical company and a subsidiary of the China National Pharmaceutical Group (Sinopharm). The company specializes in the research and development of innovative peptide drugs and small molecule therapeutics, with a primary focus on metabolic diseases such as type 2 diabetes and obesity. Its lead programs include multi-target agonists focusing on GLP-1, GIP, and Glucagon receptors. Sinopharm Nuoh leverages its proprietary peptide technology platform to develop long-acting and highly potent treatments aimed at addressing significant unmet needs in the global metabolic health market.

Therapeutic areas: EndocrinologyGastroenterologyMetabolic Disorders
Modalities: Small moleculePeptidesBiologic
Industry: Biotech

Partnerships

China National Biotec Group

Beyond the preview

Go deeper on Sinopharm Nuoh.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sinopharm Nuoh.

Explore the full profile